Traditional Chinese medicine composition for treating poor heart muscle perfusion after direct PCI surgery of heart-yang inactivation type ST-elevated myocardial infarction

Abstract

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine composition for treating poor heart muscle perfusion after a direct PCI surgery of heart-yang inactivation type ST-elevated myocardial infarction (STEMI). The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 5 to 13 parts of arisaema fargesii buchet, 4 to 8 parts of herba alyxiae sinensis, 4 to 8 parts of phlegmariurus hamiltonii, 4 to 8 parts of psoralea corylifolia, 4 to 8 parts of ginkgo biloba, 2 to 4 parts of meconopsis horridula, 4 to 8 parts of debark peony root, 4 to 8 parts of buddleja asiatica, 4 to 8 parts of plumbago indica and 4 to 8 parts of liquorice root. Various medicines are jointly used to achieve the efficacy of tonifying yang and activating heart-yang. The poor heart muscle perfusion of a patient after the direct PCI surgery of STEMI can be obviously improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating poor heart-yang myocardial perfusion after direct PCI for ST-segment elevation myocardial infarction. Background technique [0002] Direct percutaneous coronary intervention (Percutaneous coronary intervention PCI) is the main treatment for acute ST-segment elevation myocardial infarction (St-elevationmyocardialinfarctionSTEMI). However, it has been clinically found that about 30% to 40% of patients with infarct-related arteries do not improve myocardial tissue microcirculation perfusion, that is, myocardial perfusion is poor. Studies have found that myocardial perfusion is the main cause of cardiovascular events and mortality. Therefore, how to adopt which treatment method can improve myocardial perfusion after STEMI primary PCI has important clinical significance. [0003] Western medicine believes that poor...

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is to avoid the deficiencies in the above-mentioned prior art, and to provide a traditional Chinese medicine composition for treating heart-yang deficiency type ST-segment elevation myocardial infarction and poor myocardial perfusion after direct PCI